Citigroup Lowers Health Catalyst Price Target

Analysts cut price target for healthcare data and analytics company to $1.75

Mar. 13, 2026 at 8:33pm

Got story updates? Submit your updates here. ›

Citigroup has lowered its price target for Health Catalyst (NASDAQ:HCAT) from $2.75 to $1.75, while maintaining a "neutral" rating on the stock. Several other research analysts have also recently cut their price targets for the healthcare data and analytics company, citing concerns about its financial performance.

Why it matters

Health Catalyst's stock price has been under pressure in recent months as the company faces headwinds in the healthcare technology market. The lowered price targets from analysts signal concerns about the company's near-term growth prospects and profitability, which could impact investor sentiment and the stock's performance.

The details

In a note to investors, Citigroup cited the challenging market conditions facing Health Catalyst as the reason for the reduced price target. The brokerage firm noted that other analysts have also lowered their price targets for the company, with Stifel Nicolaus cutting its target from $3.75 to $2.00 and Canaccord Genuity Group lowering its target from $5.00 to $2.00. The analysts pointed to the company's financial performance and the competitive landscape in the healthcare data and analytics space as factors behind the price target reductions.

  • Citigroup lowered the price target on March 13, 2026.

The players

Health Catalyst

A healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has focused on delivering a unified data platform to help healthcare organizations aggregate and analyze clinical, financial and operational information.

Citigroup

A global financial services company that provides a wide range of banking, investing, and other financial products and services.

Stifel Nicolaus

A full-service wealth management and investment banking firm that provides securities brokerage, investment banking, trading, investment advisory, and related financial services.

Canaccord Genuity Group

A global financial services firm that provides investment banking, wealth management, and capital markets services.

Got photos? Submit your photos here. ›

The takeaway

The lowered price targets for Health Catalyst from multiple research analysts suggest the company is facing significant challenges in the healthcare technology market, which could impact its financial performance and investor sentiment in the near term. The company will need to demonstrate a clear path to profitability and growth in order to regain investor confidence.